Clear-cell renal-cell carcinoma (RCCcc) is the genitourinary neoplasm with the highest mortality rate despite primary surgical treatment, which highlights the necessity for adjuvant treatment.
Introduction
Renal cell carcinoma (RCC) accounts for 2-3% of all neoplasms [1] . An increase in incidence has been seen during the last decade because of a greater incidental diagnosis in imaging tests performed for another reason [2] . Risk factors have been identified, which include smoking, hypertension and obesity [3] . The three main types of RCC are clear cell (RCCcc), papillary type I and II (RCCp) and chromophobe (RCCch) [4] .
RCCcc is the most frequent type and has the worst prognosis [5] .
According to the TNM classification, the specific cancer survival rates for RCCcc are 91%, 74%, 67% and 32% for stages I, II, III and IV, respectively [6] . Thus, locally advanced RCCcc is one of the most lethal genitourinary malignancies, and surgery is its only curative treatment [7] .
However, the risk of recurrence after nephrectomy reaches 40%, with OS at 5 years of 30% at stage T4 and 50% in the case of lymphatic involvement [3, 8] .
To improve these results, the role of adjuvant treatments after surgery is In 2016, the S-TRAC study demonstrated an improvement in DFS in patients with locally advanced RCCcc who were treated with adjuvant sunitinib compared to those treated with placebo for 1 year after nephrectomy. This study observed only a moderate worsening in the quality of life in the patients who received sunitinib [9] . However, the other studies with VEGF inhibitors have obtained negative results, so the use of sunitinib continues to be controversial. The aim of the present study was to identify patients at high risk of recurrence according to S-TRAC criteria and select potential candidates with locally advanced RCC for adjuvant treatment in a single-center sample.
Materials and Methods
We retrospectively reviewed hospital surgical and clinical records from January 2009 to December 2014.
The study was approved by the hospital ethics committee and was conducted in accordance with
International Conference on Harmonisation Good
Clinical Practice guidelines and applicable local regulatory requirements and laws. Eligible patients were at least 18 years of age and had received a diagnosis of locoregional RCC (tumor stage 3 or higher, regional lymph-node metastasis, or both). Other eligibility criteria included histologic confirmation of RCCcc, no previous systemic treatment and a score of no more than 2 on the Eastern Cooperative Oncology Group (ECOG) scale before nephrectomy. Patients were stratified into risk groups according to the 2002 UCLA Integrated System (UISS) prognostic model: 
Results
We collected data about 153 patients subjected to nephrectomy for RCC between 2009 and 2014. 48 patients out of 153 (31.4%) met S-TRAC eligibility criteria and were subsequently selected and classified according to UISS categories. Two patients were not classifiable due to lack of complete data. Radical surgery was performed in 40 patients (81.6%) while partial nephrectomy was performed in the remaining 8 patients (16.3%). Table 1 shows study patients' baseline and oncological characteristics and their risk stratification according to the UISS classification.
Additionally, Table 1 includes placebo-and sunitinib- 
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*44% sunitinib group and 45% sorafenib group had to stop treatment because of toxicity; 55% of patients had to reduce doses due to adverse effects grade ≥ 3; ** 28% had to interrupt treatment because of toxicity; 34% of patients had to reduce doses due to adverse effects grade ≥ 3; *** The dose of the study had to be modified to 600 mg due to high toxicity with 800 mg The incidence of adverse effects was similar in both groups, although the toxicity ≥ 3 degree was greater in the axitinib group (61% vs. 30%). The OS data were not mature [16] .
Only the S-TRAC trial showed a clinical and statistically significant reduction of 24% in the occurrence of recurrence events in comparison to placebo [9, 10] . In light of the positive results of S-TRAC, the Food and Drug Administration (FDA) approved sunitinib as adjuvant therapy in high-risk RCC in November 2017 [7] . However, the European Medicines Agency (EMA) did not view the results in the same way [17] , and controversy regarding the benefit of sunitinib in the adjuvant setting continues. [21, 22] .
Beyond 
Conclusion
The management of RCCcc, especially in advanced stages, is a challenge because it represents a disease with a high risk of recurrence and mortality. To date, only the use of sunitinib as an adjuvant treatment has been approved by the FDA after the results of the S- 
